bluuebunny/crossref_metadata_2025_split huggingface dataset:
Quality of partner support moderates positive affect in patients with cancer
Authors: Kaliampos Apostolos , Roussi Pagona 
Published: February 2018

AbstractObjectiveIn the present study, we examined whether 4 support quality‐related characteristics moderate the impact of received partner support on positive affect of patients with cancer. The support quality‐related characteristics were patients' perception regarding the willingness of their partners to offer support, patients' perception that partner support is certain, patients' satisfaction with partner relationship, and overall patients' satisfaction with partner support.MethodsSeventy‐seven recently diagnosed patients with cancer were assessed at 2 time points, during chemotherapy treatment (baseline) and 7 months later (follow‐up). Two types of received support were examined, emotional support and advice‐guidance from partner. Multiple regression analyses were performed to determine the moderating effect of the quality‐related variables on the relationship between received support at baseline and patient's positive affect at 7‐month follow‐up.ResultsResults showed that all 4 quality‐related characteristics had a moderating role (f2 ranged between .06 and .16, P < .05). Emotional support predicted positive affect only when patients reported high partner willingness to offer support, considered the partner support certain, were satisfied with the partner relationship (a trend), and were satisfied with the received support. In contrast, when patients perceived their partners as unwilling to provide support and were dissatisfied with the relationship, support (both emotional and advice‐guidance and advice‐guidance, respectively) exhibited a negative impact on positive affect.ConclusionsThe findings suggest that only when the quality of support is high does social support have a positive impact on patients' positive affect.
Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis
Authors: Kopp Benjamin T. , McCulloch Scott , Shrestha Chandra L. , Zhang Shuzhong , Sarzynski Lisa , Woodley Frederick W. , Hayes Don 
Published: February 2018

AbstractBackgroundCystic fibrosis (CF) is a life‐limiting disease caused by a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Lumacaftor/Ivacaftor is a novel CFTR modulator approved for patients that are homozygous for Phe508del CFTR, but its clinical effectiveness varies amongst patients, making it difficult to determine clinical responders. Therefore, identifying biochemical biomarkers associated with drug response are clinically important for follow‐up studies.MethodsSerum metabolomics was performed on twenty patients with CF pre‐ and 6‐month post‐Lumacaftor/Ivacaftor response via Ultrahigh Performance Liquid Chromatography‐Tandem Mass Spectroscopy (UPLC‐MS/MS). Correlation with clinical variables was performed.ResultsMetabolomics analysis demonstrated 188 differentially regulated metabolites between patients pre‐ and post‐Lumacaftor/Ivacaftor initiation, with a predominance of lipid and amino acid alterations. The top 30 metabolites were able to differentiate pre‐ and post‐Lumacaftor/Ivacaftor status in greater than 90% of patients via a random‐forest confusion matrix. Alterations in bile acids, phospholipids, and bacteria‐associated metabolites were the predominant changes associated with drug response. Importantly, changes in metabolic patterns were associated with clinical responders.ConclusionsSelected key lipid and amino acid metabolic pathways were significantly affected by Lumacaftor/Ivacaftor initiation and similar pathways were affected in clinical responders. Targeted metabolomics may provide useful and relevant biomarkers of CFTR modulator responses.
Complex HuR function in pancreatic cancer cells
Authors: Brody Jonathan R. , Dixon Dan A. 
Published: February 2018

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with dismal patient outcomes. The underlying core genetic drivers of disease have been identified in human tumor specimens and described in genetically engineered mouse models. These genetic drivers of PDAC include KRAS signaling, TP53 mutations, and genetic loss of the SMAD4 tumor suppressor protein. Beyond the known mutational landscape of PDAC genomes, alternative disrupted targets that extend beyond conventional genetic mutations have been elusive and understudied in the context of PDAC cell therapeutic resistance and survival. This last point is important because PDAC tumors have a unique and complex tumor microenvironment that includes hypoxic and nutrient‐deprived niches that could select for cell populations that garner therapeutic resistance, explaining tumor heterogeneity in regards to response to different therapies. We and others have embarked in a line of investigation focused on the key molecular mechanism of posttranscriptional gene regulation that is altered in PDAC cells and supports this pro‐survival phenotype intrinsic to PDAC cells. Specifically, the key regulator of this mechanism is a RNA‐binding protein, HuR (ELAVL1), first described in cancer nearly two decades ago. Herein, we will provide a brief overview of the work demonstrating the importance of this RNA‐binding protein in PDAC biology and then provide insight into ongoing work developing therapeutic strategies aimed at targeting this molecule in PDAC cells.This article is categorized under:

RNA in Disease and Development > RNA in Disease
Cover Image, Volume 9, Issue 2
Authors: Nutter Curtis A. , Kuyumcu‐Martinez Muge N. 
Published: February 2018

The cover image, by Curtis A. Nutter and Muge N. Kuyumcu‐Martinez, is based on the Advanced Review Emerging roles of RNA‐binding proteins in diabetes and their therapeutic potential in diabetic complications, DOI: 10.1002/wrna.1459.
image
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
Authors: Stathis Anastasios , Flinn Ian W. , Madan Sumit , Maddocks Kami , Freedman Arnold , Weitman Steven , Zucca Emanuele , Munteanu Mihaela C. , Lia Palomba M. 
Published: February 2018

Summary
Background CD37 is expressed on B-cell lymphoid malignancies, thus making it an attractive candidate for targeted therapy in non-Hodgkin lymphoma (NHL). IMGN529 is an antibody-drug conjugate comprising a CD37-binding antibody linked to the maytansinoid DM1, a potent anti-mitotic agent. Methods This first-in-human, phase 1 trial recruited adult patients with relapsed or refractory B-cell NHL. The primary objective was to determine the maximum tolerated dose (MTD) and recommended phase 2 dose. Secondary objectives were to evaluate safety, pharmacokinetics, and preliminary clinical activity. IMGN529 was administered intravenously once every 3 weeks, and dosed using a conventional 3 + 3 dose-escalation design. Results Forty-nine patients were treated at doses escalating from 0.1 to 1.8 mg/kg. Dose limiting toxicities occurred in eight patients and included peripheral neuropathy, febrile neutropenia, neutropenia, and thrombocytopenia. The most frequent treatment-emergent adverse events were fatigue (39%), neutropenia, pyrexia, and thrombocytopenia (each 37%). Adverse events led to treatment discontinuation in 10 patients (20%). Eight patients (16%) had treatment-related serious adverse events, the most common being grade 3 febrile neutropenia. The MTD (with growth factor support) was 1.4 mg/kg every 3 weeks. IMGN529 plasma exposure increased monotonically with dose and was consistent with target-mediated drug disposition. Five (13%) of 39 response-evaluable patients achieved an objective response (one complete response and four partial responses), four of which occurred in the subgroup of patients with diffuse large B-cell lymphoma. Conclusions The manageable safety profile of IMGN529 and preliminary evidence of activity, particularly in DLBCL patients, support the continued development of this novel CD37-targeting agent.
Clinical and genetic aspects of Mayer–Rokitansky–Küster–Hauser syndrome
Authors: Ledig Susanne , Wieacker Peter 
Published: February 2018

AbstractThe Mayer–Rokitansky–Küster–Hauser (MRKH) syndrome [MIM 277000] is characterised by the absence of a uterus and vagina in otherwise phenotypically normal women with karyotype 46,XX. Clinically, the MRKH can be subdivided into two subtypes: an isolated or type I form can be delineated from a type II form, which is characterised by extragenital malformations. The so-called Müllerian hypoplasia, renal agenesis, cervicothoracic somite dysplasia (MURCS) association can be seen as the most severe phenotypic outcome.The MRKH syndrome affects at least 1 in 4000 to 5000 female new-borns. Although most of the cases are sporadic, familial clustering has also been described, indicating a genetic cause of the disease. However, the mode of inheritance is autosomal-dominant inheritance with reduced penetrance. High-resolution array-CGH and MLPA analysis revealed recurrent aberrations in different chromosomal regions such as TAR susceptibility locus in 1q21.1, chromosomal regions 16p11.2, and 17q12 and 22q11.21 microduplication and -deletion regions in patients with MRKH. Sequential analysis of the genesLHX1, TBX6andRBM8A, which are located in chromosomal regions 17q12, 16p11.2 and 1q21.1, yielded in the detection of MRKH-associated mutations. In a subgroup of patients with signs of hyperandrogenaemia mutations ofWNT4have been found to be causative. Analysis of another member of the WNT family,WNT9B, resulted in the detection of some causative mutations in MRKH patients.
Preliminary Validation of a German Version of the Sexual Complaints Screener for Women in a Female Population Sample
Authors: Burri Andrea , Porst Hartmut 
Published: February 2018

Abstract

Background
To date, neither the original English nor any of the translated versions of the Sexual Complaints Screener for Women (SCS-W) have been tested for their psychometric properties.

Aim
To evaluate the validity and utility of the German version of the SCS-W by assessing content, convergent, and discriminant validity.

Methods
A population sample of 309 women (mean age = 26.9 years) completed the online survey and had matching data available on the SCS-W and the Female Sexual Function Index (FSFI). Spearman bivariate correlations between the SCS-W and FSFI domain scores and exploratory factor analysis with principal component analysis were conducted.

Outcomes
Convergent validity was excellent for the domain of orgasm, good for satisfaction, dyspareunia, and the total questionnaire score, and acceptable for desire, lubrication, arousal, and vaginismus. Discriminant validity was present for all domains apart from arousal, lubrication, and vaginismus. Varimax rotation suggested an 8-factor model was the most robust.

Clinical Implications
This brief screener seems suitable to provide a brief overview of female patients' sexual problems in a clinical setting.

Strengths and Limitations
This is the 1st study to assess the psychometric properties of the German version of the SCS-W. However, available information on the psychometric properties of the German SCS-W was limited because the validity of the screener could not be counterchecked against a clinical diagnosis of female sexual dysfunction.

Conclusion
Our results provide preliminary evidence of good validity of the German version of the SCS-W. Overall, the SCS-W can offer support for clinicians who are less familiar with sexual medicine and who might not routinely discuss sexual issues with their patients.
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
Authors: Hanon Olivier , Vidal Jean‐Sébastien , Lehmann Sylvain , Bombois Stéphanie , Allinquant Bernadette , Tréluyer Jean‐Marc , Gelé Patrick , Delmaire Christine , Blanc Fredéric , Mangin Jean‐François , Buée Luc , Touchon Jacques , Hugon Jacques , Vellas Bruno , Galbrun Evelyne , Benetos Athanase , Berrut Gilles , Paillaud Elèna , Wallon David , Castelnovo Giovanni , Volpe‐Gillot Lisette , Paccalin Marc , Robert Philippe‐Henri , Godefroy Olivier , Dantoine Thierry , Camus Vincent , Belmin Joël , Vandel Pierre , Novella Jean‐Luc , Duron Emmanuelle , Rigaud Anne‐Sophie , Schraen‐Maschke Suzanna , Gabelle Audrey ,   on behalf of the BALTAZAR study group
Published: February 2018

AbstractIntroductionDiagnostic relevance of plasma amyloid β (Aβ) for Alzheimer's disease (AD) process yields conflicting results. The objective of the study was to assess plasma levels of Aβ42and Aβ40in amnestic mild cognitive impairment (MCI), nonamnestic MCI, and AD patients and to investigate relationships between peripheral and central biomarkers.MethodsOne thousand forty participants (417 amnestic MCI, 122 nonamnestic MCI, and 501 AD) from the Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk multicenter prospective study with cognition, plasma, cerebrospinal fluid (CSF), and magnetic resonance imaging assessments were included.ResultsPlasma Aβ1–42and Aβ1–40were lower in AD (36.9 [11.7] and 263 [80] pg/mL) than in amnestic MCI (38.2 [11.9] and 269 [68] pg/mL) than in nonamnestic MCI (39.7 [10.5] and 272 [52] pg/mL), respectively (P = .01 for overall difference between groups for Aβ1–42andP = .04 for Aβ1–40). Globally, plasma Aβ1–42correlated with age, Mini–Mental State Examination, andAPOE ε4 allele. Plasma Aβ1–42correlated with all CSF biomarkers in MCI but only with CSF Aβ42in AD.DiscussionPlasma Aβ was associated with cognitive status and CSF biomarkers, suggesting the interest of plasma amyloid biomarkers for diagnosis purpose.
Defibulation: A Visual Reference and Learning Tool
Authors: Abdulcadir Jasmine , Marras Sandra , Catania Lucrezia , Abdulcadir Omar , Petignat Patrick 
Published: February 2018

Abstract
Female genital mutilation type III (infibulation) is achieved by narrowing the vaginal orifice by creating a covering seal, accomplished by cutting and appositioning the labia minora and/or labia majora, with or without clitoral excision. Infibulation is responsible for significant urogynecological, obstetrical, and psychosexual consequences that can be treated with defibulation (or de-infibulation), an operation that opens the infibulation scar, exposing the vulvar vestibule, vaginal orifice, external urethral meatus, and eventually the clitoris. This article provides a practical comprehensive, up-to-date visual learning tool on defibulation, with information on pre-operative, post-operative, and follow-up information.
The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): Trends in Prevalence, Treatment, and Regrets
Authors: Wiepjes Chantal M. , Nota Nienke M. , de Blok Christel J.M. , Klaver Maartje , de Vries Annelou L.C. , Wensing-Kruger S. Annelijn , de Jongh Renate T. , Bouman Mark-Bram , Steensma Thomas D. , Cohen-Kettenis Peggy , Gooren Louis J.G. , Kreukels Baudewijntje P.C. , den Heijer Martin 
Published: February 2018

Abstract

Background
Over the past decade, the number of people referred to gender identity clinics has rapidly increased. This raises several questions, especially concerning the frequency of performing gender-affirming treatments with irreversible effects and regret from such interventions.

Aim
To study the current prevalence of gender dysphoria, how frequently gender-affirming treatments are performed, and the number of people experiencing regret of this treatment.

Methods
The medical files of all people who attended our gender identity clinic from 1972 to 2015 were reviewed retrospectively.

Outcomes
The number of (and change in) people who applied for transgender health care, the percentage of people starting with gender-affirming hormonal treatment (HT), the estimated prevalence of transgender people receiving gender-affirming treatment, the percentage of people who underwent gonadectomy, and the percentage of people who regretted gonadectomy, specified separately for each year.

Results
6,793 people (4,432 birth-assigned male, 2,361 birth-assigned female) visited our gender identity clinic from 1972 through 2015. The number of people assessed per year increased 20-fold from 34 in 1980 to 686 in 2015. The estimated prevalence in the Netherlands in 2015 was 1:3,800 for men (transwomen) and 1:5,200 for women (transmen). The percentage of people who started HT within 5 years after the 1st visit decreased over time, with almost 90% in 1980 to 65% in 2010. The percentage of people who underwent gonadectomy within 5 years after starting HT remained stable over time (74.7% of transwomen and 83.8% of transmen). Only 0.6% of transwomen and 0.3% of transmen who underwent gonadectomy were identified as experiencing regret.

Clinical Implications
Because the transgender population is growing, a larger availability of transgender health care is needed. Other health care providers should familiarize themselves with transgender health care, because HT can influence diseases and interact with medication. Because not all people apply for the classic treatment approach, special attention should be given to those who choose less common forms of treatment.

Strengths and Limitations
This study was performed in the largest Dutch gender identity clinic, which treats more than 95% of the transgender population in the Netherlands. Because of the retrospective design, some data could be missing.

Conclusion
The number of people with gender identity issues seeking professional help increased dramatically in recent decades. The percentage of people who regretted gonadectomy remained small and did not show a tendency to increase.
Aggregatibacter (Actinobacillus) actimycetemcomitans leukotoxin and human periodontitis – A historic review with emphasis on JP2
Authors: Tsai Chi‐Cheng , Ho Ya‐Ping , Chou Yu‐Shian , Ho Kun‐Yen , Wu Yi‐Min , Lin Ying‐Chu 
Published: February 2018

AbstractAggregatibacter (Actinobacillus) actimycetemcomitans (Aa) is a gram‐negative bacterium that colonizes the human oral cavity and is causative agent for localized aggressive (juvenile) periodontitis (AgP). In the middle of 1990s, a specific JP2 clone of belonging to the cluster of serotype b strains of Aa with highly leukotoxicity (leukotoxin, LtxA) able to kill human immune cells was isolated. JP2 clone of Aa was strongly associated with in particularly in rapidly progressing forms of aggressive periodontitis. The JP2 clone of Aa is transmitted through close contacts. Therefore, AgP patients need intense monitoring of their periodontal status as the risk for developing severely progressing periodontitis lesions are relatively high. Furthermore, timely periodontal treatment, including periodontal surgery supplemented by the use of antibiotics, is warranted. More importantly, periodontal attachment loss should be prevented by early detection of the JP2 clone of Aa by microbial diagnosis testing and/or preventive means.
Fibromixoma acral superficial: Revisão da Literatura
Authors: Crepaldi Bruno Eiras , Soares Ruan Dalbem , Silveira Fábio Duque , Taira Raul Itocazo , Hirakawa Celso Kiyoshi , Matsumoto Marcelo Hide 
Published: February 2018

ResumoO fibromixoma acral superficial é um tumor raro de tecidos moles. Geralmente se manifesta por meio de uma massa indolor de crescimento lento que acomete principalmente adultos do sexo masculino na quinta década de vida. Ele normalmente afeta a região distal, com aparência polipoide. A aparência histológica é de uma massa dérmica sem cápsula, com fibroblastos fusiformes em estroma mixocolagenoso. A avaliação imuno-histoquímica do fibromixoma acral superficial normalmente é positiva para CD34 e CD99, com positividade variável para o antígeno epitelial de membrana. O tratamento consiste na exérese completa da massa tumoral.Foi feita uma revisão da literatura atual sobre o fibromixoma acral superficial com ênfase na quantidade de casos relatados, na localização, nos métodos diagnósticos, nas características histológicas, nos diagnósticos diferenciais, e no tratamento.Foram encontrados na literatura atual 314 casos descritos de fibromixoma acral superficial com localização variada, principalmente em pododáctilos (45,8%) e quirodáctilos (39,1%). Este tumor tem acometimento ligeiramente superior em homens (61%), e enorme variabilidade na faixa etária de acometimento.O fibromixoma acral superficial é um tumor de tecido mole único que deve entrar no diagnóstico diferencial das lesões periungueais e subungueais acrais; o tratamento consiste da exérese simples. Mais estudos são necessários para que se conheça melhor essa patologia, descrita em 2001.
Eficácia do antibiótico profilático intraósseo versus endovenoso em cirurgias do joelho em porcos: Estudo experimental
Authors: Mattos Carlos Augusto de , Santos Nina Razzo Pereira dos , Cyrino Mariana de Oliveira , Credidio Laura , Virgilli Natália Silveira , Simões Neto Joaquim 
Published: February 2018

Resumo
Objetivo Demonstrar, em 36 porcos usados como modelos vivos, que o acesso intraósseo (IO) é mais eficaz em comparação com o acesso endovenoso (EV) na administração de antibiótico profilático em cirurgias na articulação do joelho.
Materiais e Métodos Foram coletadas, analisadas e comparadas amostras de pele, tecido subcutâneo, cartilagem e osso, após administração de antibiótico profilático EV e IO em grupos diferentes.
Resultado A comparação entre os grupos IO e EV indicou que no grupo IO houve maior concentração de antibiótico profilático na pele (p = 0,049), na cartilagem (p = 0,018) e no osso (p = 0,002), na análise das primeiras 24 horas após 30 minutos de infusão.
Conclusão Visto que as complicações dessa prática são raras, o uso dessa via pode ser uma opção para a diminuição do risco de infecção do sítio cirúrgico nas cirurgias ortopédicas, pois leva à diminuição da morbimortalidade e dos gastos hospitalares com reabordagens ou com tempo prolongado de internação. Contudo, são necessários mais pesquisas e novos estudos experimentais em seres humanos, dado que está comprovada a eficácia do método em porcos.
Ruptura atraumática bilateral do ligamento patelar—relato de caso
Authors: Juliato Raul , Boschi Luis , Juliato Raul , Freitas Americo , França Alexandre , Bottura Lourenço 
Published: February 2018

ResumoA ruptura atraumática bilateral do ligamento patelar é uma lesão rara, geralmente associada a doenças sistêmicas e ao uso de medicamentos como corticoides e fluoroquinolonas. Este relato apresenta um caso de rotura atraumática bilateral do ligamento patelar em um homem de 43 anos, portador de obesidade, diabetes melitus tipo 2 e em uso de corticoide sistêmico para doença autoimune (granulomatose de Wegener). Esses fatores provocam alterações degenerativas e inflamatórias crônicas nos ligamentos, confirmadas pelo exame histológico. Devido à qualidade tecidual, foi feito reparo primário do ligamento associado a reforço com o tendão semitendíneo. Após um ano, o paciente apresentou evolução satisfatória, com ganho de amplitude de movimento completo e retorno às atividades habituais, sem sequelas.